Related references
Note: Only part of the references are listed.Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study
Wei-Chen Lin et al.
INFLAMMATORY BOWEL DISEASES (2023)
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis
Mohamed Attauabi et al.
DIGESTIVE AND LIVER DISEASE (2022)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Tim Raine et al.
JOURNAL OF CROHNS & COLITIS (2022)
Original Article The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
Chia-Jung Kuo et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2022)
Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Waseem Ahmed et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review
Ashwin N. Ananthakrishnan et al.
GASTROENTEROLOGY (2021)
A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib
Pilar Taberner Bonastre et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2021)
Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study
Jeongseok Kim et al.
INFLAMMATORY BOWEL DISEASES (2021)
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study
Laurent Goessens et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Clinical outcomes of vedolizumab maintenance treatment for Korean patients with inflammatory bowel disease who failed anti-TNF therapy: A KASID prospective multicenter cohort study
K. Oh et al.
JOURNAL OF CROHNS & COLITIS (2021)
The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
Byong Duk Ye et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
Choon Jin Ooi et al.
INTESTINAL RESEARCH (2021)
Incidence and Prevalence of Inflammatory Bowel Disease across Asia
Jihye Park et al.
YONSEI MEDICAL JOURNAL (2021)
Real-world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan
Yu-Chiao Chiu et al.
ADVANCES IN DIGESTIVE MEDICINE (2021)
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data
Russell D. Cohen et al.
JOURNAL OF CROHNS & COLITIS (2020)
Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab
Anastasia Dupre et al.
RHEUMATOLOGY (2020)
Long-term safety of vedolizumab for inflammatory bowel disease
Edward V. Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the east Midlands UK - a retrospective observational study
Jonathan R. White et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2020)
Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?
Marjorie Argollo et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study
Nathaniel Aviv Cohen et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)
Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
Rupa Banerjee et al.
GUT AND LIVER (2020)
Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study
Preeti Shashi et al.
GASTROENTEROLOGY REPORT (2020)
Real-world data on the efficacy and safety of vedolizumab therapy in patients with inflammatory bowel disease: a retrospective nation-wide cohort study in Singapore
A. T. -M. Gan et al.
JOURNAL OF CROHNS & COLITIS (2019)
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Tal Engel et al.
JOURNAL OF CROHNS & COLITIS (2018)
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Neeraj Narula et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medica Records
Hun-Sung Kim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2018)
Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease
Paulo G. Kotze et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting
Siew C. Ng et al.
INFLAMMATORY BOWEL DISEASES (2018)
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort
S. Tadbiri et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Immunological pathogenesis of inflammatory bowel disease
Seung Hoon Lee et al.
INTESTINAL RESEARCH (2018)
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Edward V. Loftus et al.
JOURNAL OF CROHNS & COLITIS (2017)
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Tim Wyant et al.
JOURNAL OF CROHNS & COLITIS (2016)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Share Paper
